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Aims: To monitor the association between the course of high risk human papillomavirus (HR-HPV) infection
and the development of cervical neoplasia over time, from a baseline of normal cervical cytology.
Methods: This paper presents the follow up data from a previous cross sectional analysis. Women from a
screening population who had normal cytology and who were HR-HPV positive were recalled after two to
three years for cytology and HPV genotyping. The development of cervical neoplasia at follow up was
related to the course of HPV infection (clearance, persistence, or sequential infection) and the presence of
single or multiple HPV infections at baseline. A comparator control group of women who were HPV and
cytologically negative at baseline were selected from the same population.
Results: Twelve cases of dyskaryosis were found in women who were HPV positive at baseline; four were
high grade. Only three cases of low grade dyskaryosis were found in the control group. Women with type
specific persistent infections were significantly more likely to develop cervical neoplasia than women who
cleared the infection (p = 0.0001) or were sequentially infected with different types (p = 0.001). Women
with multiple HPV infections at baseline were no more likely to develop cervical dyskaryosis than those with
a single infection.
Conclusions: Type specific persistent HR-HPV infection as monitored by genotyping can identify women at
increased risk of cervical neoplasia more accurately than a single or repeated presence/absence HPV test.
The cost effectiveness of such an approach should be investigated by an appropriate, large scale cost–
benefit analysis.
I
nfection with high risk human papillomavirus (HR-HPV) is
necessary for the development of cervical cancer and its
associated precursor, cervical intraepithelial neoplasia.1 2
However, genital HPV infection is common, especially in
young women, and frequently shows a transient course.1 This
reduces the effectiveness of a single HPV detection test in
terms of specificity for prediction of progressive disease. A
summary of the experts’ meeting at the EUROGIN 2003
conference stated that ‘‘persistent infection (with HPV) is the
single best predictor of cervical cancer’’.2 This conclusion was
based on longitudinal studies that monitored the course of
HPV infection and its impact on cancer progression. Some of
these studies included tests that detect the presence/absence
of at least one of a pool of ‘‘common’’ HR-HPV types, such as
the Digene hybrid captureH 2 test.3 4 There are benefits to
such a test, which include ease of result interpretation and
amenability to automation. However, sequential positive
results do not identify the persistence of a specific type of
HPV, whereas HPV genotyping assays can delineate specific
types and are thus more suited to detecting persistent
infection. Genotyping can also detect multiple HPV infec-
tions, although the clinical usefulness of this diagnosis
remains controversial.
‘‘Human papillomavirus genotyping assays can delineate
specific types and are thus more suited to detecting
persistent infection’’
Few studies have compared HPV persistence, as monitored
by an HPV genotyping approach, with a presence/absence
HPV test over time.5 6 If HPV testing does become incorpo-
rated within screening, determining which type of HPV test is
the most informative and cost effective is crucial.
We previously reported on a group of 3444 women from a
routine cervical screening population in which HPV positivity
and prevalence of multiple HR-HPV infections was related to
age and grade of cervical neoplasia.7 A cohort of 126 women
who were HR-HPV positive at baseline with normal cytology
(fig 1) agreed to have follow up cytology and HPV genotyping
Target group
Cervical
cytology and
HPV DNA test,
2002/2003
HPV DNA +ve
n = 392
Control group
Cervical
cytology and
HPV DNA test,
2003
HPV DNA –ve
n = 2697
Subject to
standard
clinical recall
Women with
normal cervical
cytology
Sample of 3444 liquid based cytology cervical specimens collected
from a routine screening population in 2000 – all tested for HPV
Women with
abnormal cervical
cytology
Figure 1 Recruitment of study participants: target and control groups
and human papillomavirus (HPV) testing strategy.
Abbreviations: HPV, human papillomavirus; HR, high risk; LBC, liquid
based cytology
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two to three years later. These samples were analysed for
evidence of cervical neoplasia and its relation to three HPV
related factors, namely: (1) HR-HPV infection at baseline
versus absence, (2) multiple HR-HPV infections at baseline
versus single HR-HPV infection, and (3) type specific HR-
HPV persistence compared with sequential infection by
different HPV types and clearance of HPV infection.
MATERIALS AND METHODS
Recruitment of study participants and recall strategy
Women were recruited from the screening population
through general practitioner practices across Edinburgh,
Scotland, as described previously.1 In total, 126 women who
were cytology negative and HPV positive in 2000 (baseline)
returned for a liquid based cytology (LBC) sample to be taken
and HPV testing carried out (mean recall period, 2.2 years).
This group of women was termed the ‘‘target group’’ and had
a median age of 29.6 years. LBC samples were also obtained
from a control group of 99 women from the same population
who were negative for cytology and HPV at baseline in 2000,
and who consented to repeat cytology and HPV testing at
follow up (mean recall, 3.1 years; median age, 37.5 years).
Written consent was obtained from all study participants and
ethics approval was obtained from the Lothian research
ethics committee.
Cervical cytological grading and HPV testing
Flat layer slides were made by the ThinPrepH procedure.
Cervical cytological grading was performed according to
British Society for Clinical Cytology guidelines. Nucleic acid
extraction of LBC material was performed as described
previously.8 HPV detection and genotyping were performed
by application of GP5+/6+ real time polymerase chain
reaction and a reverse line blot assay containing 18 high risk
HPV probes and nine low risk HPV probes (Roche Molecular
Systems, Alameda, California, USA).9–11
Association between HPV status and evidence of
cervical neoplasia at follow up
Analysis of the association between the baseline HPV result
and cervical neoplasia follow up at in the target and control
groups was performed by the x2 test, with confidence
intervals for differences in proportions. Logistic regression
was performed with follow up cervical neoplasia status as the
outcome and HPV at baseline (single v multiple HPV
infection) and age (( 30 v . 30) as the predictors. Women
who had persistent HPV infection (defined as at least one
HPV of the same type being present in both baseline and
follow up samples) were compared (in terms of number of
cases with cervical neoplasia at follow up) with those who
were HPV positive at baseline but negative at follow up
(clearance of HPV infection) and those who were HPV
positive at baseline but who tested positive for different HPV
type(s) at follow up (sequential HPV infection). Women were
age stratified within these three groups. Fisher’s exact test
was used to analyse the difference in proportions between
women of ( 30 versus . 30 years of age and cervical
neoplasia associated with persistence of HPV infection.
RESULTS
HPV status at baseline and its relation to cervical
neoplasia at follow up
A total of 16 of 126 women within the target group had
detectable cervical neoplasia at follow up: 12 with low grade
abnormalities (borderline or mild dyskaryosis) and four with
high grade cervical neoplasia (moderate or severe dyskar-
yosis). In the control group, three women exhibited low
grade cervical neoplasia at follow up.
Table 1 shows the baseline HPV status in relation to the
cytology result at follow up of women in both the target and
control groups. All dyskaryotic grades (borderline, mild,
moderate, or severe dyskaryosis) were combined into an
‘‘abnormal cytology’’ category to allow for comparison of
baseline HPV positive versus HPV negative status for
development of any cervical neoplasia at follow up. Chi
square analysis revealed that women were significantly more
likely to develop cervical neoplasia if infected with any HR-
HPV at baseline compared with HPV negative controls
(p = 0.010). Of the women in the target group, 32.5% had
multiple HR-HPV infections at baseline yet were no more
likely to develop abnormalities at follow up than women who
were infected with a single type (p = 0.650). Logistic
regression analysis revealed this finding was consistent when
women were subdivided into ( 30 and .30 years of age.
Analysis of the type specific HPV infection detected in women
who developed cervical neoplasia showed that persistent
infection by either HPV-16 or HPV-18 is associated with high
Table 1 Human papillomavirus (HPV) status and relation to cytological evidence of cervical neoplasia at follow up
Follow up cervical cytology result
HPV 2ve at baseline
(control)
HPV +ve at baseline
(target)
Single HPV type at
baseline (target)
Multiple HPV types at
baseline (target)
Normal 96 110 75 35
Borderline 2 3 3 0
Mild 1 9 4 5
Moderate 0 2 1 1
Severe 0 2 2 0
All 99 126 85 41
HPV status: negative or positive for high risk HPV at baseline, separated into single or multiple high risk HPV infection.
Table 2 Results of human papillomavirus (HPV)
genotyping at baseline and follow up in women who had
any cervical dyskaryosis detected at follow up
Follow up cytology result HPV at baseline HPV at follow up
Borderline* X` 45
Borderline* X` 39
Borderline* 16 16
Borderline Negative 35
Borderline Negative X`
Mild* 56, 73 56
Mild* 16, 58 16, 58
Mild* 33, 58 33, 82
Mild* 16, 52, 82, 6, 42 16, 53
Mild* 31 Negative
Mild* 59 39, 56, 59
Mild* 6 73, 11
Mild* 16 16, 33
Mild* 16, 58 16, 58
Mild Negative 31, 73, 53
Moderate* 16 16
Moderate* 18 18
Severe* 16 16
Severe* 16 16
*Woman within the target group; woman within the control group;
`HPV type that could not be identified by the reverse line blot assay.
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grade dyskaryosis, whereas a wider range of HPV types was
associated with low grade dyskaryosis (table 2).
Natural history of HPV infection and its relation to age
and development of cervical neoplasia
In total, 56 of 126 (44%) women in the target group were
negative for HPV at follow up, indicating clearance of the
HPV infection. In contrast, 70 of 126 (56%) remained HPV
positive, with 29 of 67 being persistently infected (by at least
one HR-HPV type) and 38 of 67 testing positive for a different
HPV type or types (sequential HPV infection) at follow up. It
was not possible to assign the three women who tested
positive for unknown HPV types at both time points to the
sequential or persistent infection groups, so they were
omitted from the analysis. The extent of HPV clearance,
persistent infection, and sequential infection was analysed
according to age (fig 2; table 3).
Sequential HPV infection decreased with age and a peak of
persistent HPV infection was found in the 21–30 year olds.
Total clearance of HPV was at its lowest in women under 30
years of age, which was reflected in the higher sequential
HPV infection levels seen in this age group compared with
women over 30 years.
Table 4 shows the course of HPV infection in relation to
cytological result at follow up. Of the 29 individuals with
persistent HR-HPV infections, 12 went on to develop
neoplasia: eight low grade (borderline and mild) and four
high grade (moderate and severe) dyskaryosis. Of those with
sequential infections, three of 38 developed neoplasia (all low
grade) and only one of 56 women who cleared their infection
developed a low grade neoplasia. Thus, those who had
persistent HR-HPV infection were more likely to develop
neoplasia than those who cleared the infection (p = 0.0001;
x2 test) or those who were sequentially infected by different
types (p = 0.001; x2 test).
Further analysis was performed to assess whether any
specific HPV types were more or less likely to persist. Table 5
shows the frequency of HPV types at baseline and the
frequency of the same HPV type at follow up. For individuals
with multiple HPV infections, each individual HPV type was
counted and analysed for persistence.
Analysis of the likelihood of persistence of the individual
types could not be performed by formal statistics because our
type specific data were to small; however, some HPV types
appeared to be more easily eradicated than others—for
example, HPV-73 and HPV-51. In addition, comparison of
the total HR and total low risk HPV types detected showed
that the HR-HPVs (34 of 133) were more likely to form
persistent infections than the low risk HPVs (three of 27),
with the difference in proportions being 14.5% (95%
confidence interval, 0.5% to 25.4%; p = 0.135; Fishers exact
test).
The number of cases of cervical neoplasia was stratified by
age and compared with the relevant course of underlying
HPV infection (table 6). We found the highest proportion of
persistent HR-HPV infection in the 21–30 year olds, although
this group did not show an increase in associated cervical
neoplasia. Using a binomial test for difference in proportions,
no significant differences in the proportions of cervical
neoplasia cases (with low and high grade dyskaryosis being
assessed cumulatively) were associated with HPV persistence
in the under 30 year olds compared with the over 30 year
olds. Numbers were too small to perform this analysis with
respect to high grade cervical neoplasia exclusively. However,
it is notable that of the four women who were . 45 years old
with persistent HR-HPV infection, three developed cervical
neoplasia, with two being of high grade.
DISCUSSION
In our study, the strength of HPV genotyping lay in the
identification of clearance, persistence, or sequential infec-
tion, rather than the identification of multiple HPV infec-
tions. Multiple HR-HPV infections did not constitute a higher
risk factor for the development of cervical neoplasia over two
to three years compared with single HR-HPV infection. In our
previous cross sectional study, we found that multiple HPV
infections were more common in young women.7 However,
no age dependent risk of cervical neoplasia associated with
multiple HPV infections was detected in our present study
when women under and over 30 were compared. These
findings are consistent with the data of Rolo´n et al.6
Our key finding was that women who harboured persistent
HR-HPV were significantly more likely to develop cervical
neoplasia than those who were sequentially infected by
different HR-HPV types or who cleared their infection. This
reinforces the elegant work by Kjaer et al, who studied type
specific HPV persistence prospectively, and that of Wallin
et al, who monitored HPV type specific persistence before
the development of cervical cancer.12 13
Although the number of cases of cervical neoplasia was
small, it was notable that no women , 30 years developed
high grade cervical neoplasia over the two to three year time
frame of our study, despite the highest proportion of
persistent HPV infections being seen in the 21–30 year old
age group. However, HPV variant analysis was not per-
formed, so it could be that individuals who showed the same
Persistent infection
Sequential infection
Total clearance
70
60
40
50
30
20
0
10
Age band (years)
%
 W
om
en
>4530–45<21 21–30
Figure 2 Course of persistent, sequential, and cleared human
papillomavirus (HPV) infection according to age.
Table 3 Natural history of human papillomavirus (HPV) infection (clearance, persistence, or sequential infection) in women
who tested HPV positive at baseline
Age at baseline (years) Number tested
Total clearance
No. (%)
Sequential infection
No. (%)
Persistent infection
No. (%)
,21 27 10 (37.0) 12 (44.4) 5 (18.5)
21–30 36 12 (33.3) 13 (36.1) 11 (30.6)
31–45 39 20 (51.3) 10 (25.6) 9 (23.1)
.45 21 14 (66.7) 3 (14.3) 4 (19.0)
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HR-HPV type at baseline and follow up were, in fact,
sequentially infected with the same type. This phenomenon
could be particularly pronounced in the 21–30 year olds who
(as seen in our study) experience a high frequency of
sequential HPV infections, probably associated with greater
sexual activity.14
All cases of high grade cervical neoplasia were seen in
women . 30 years and all were associated with type specific
persistent HR-HPV infection. In particular, of the 21 women
. 45 years of age, four harboured persistent HPV infection,
and three of these developed neoplasia (two high grade). In
addition, there were no cases of ‘‘any grade’’ of cervical
neoplasia associated with a non-persistent HPV infection in
the . 45 year olds. Repeated HPV genotyping could be used
to identify persistent HPV infection and perhaps this
approach would be most useful in cervical screening
programmes in women . 30.15 Certainly, the high prevalence
of HPV in young women and the benign nature of most of
their abnormalities have influenced screening policies in
other countries. For example, in the Netherlands and
Norway, cervical screening is not initiated until age 30 and
the Food and Drug Administration in the USA has
recommended HPV testing in combination with cytology for
primary screening in women . 30 years.16
‘‘A single human papillomavirus (HPV) test that can detect
or predict HPV persistence would be extremely useful
within a screening context’’
Extrapolation of our results suggests that repeated
genotyping might be more specific for identifying those
women at risk of cervical neoplasia compared with repeated
testing using a presence/absence HPV test. In our small study,
over 40% of women with HR-HPV persistence developed
cervical neoplasia at follow up compared with 8% who were
sequentially infected, and high grade dyskaryosis was not
seen in this last group.
Within the literature there is no clear consensus definition
of persistent HPV infection, so that if repeated genotyping is
to be used to identify persistence, an appropriate time
between tests must be defined. In addition, repeated testing
would have cost and laboratory implications. We are not
aware of an algorithm that has factored in identification of
type specific persistent HPV infection and impact on disease
detection and associated referrals.
A single HPV test that can detect or predict HPV persistence
would be extremely useful within a screening context. RNA
based approaches may be suitable, in that transcribed HPV
oncogenes directly relevant to neoplasia are targeted rather
than the structural gene L1, the classic target for DNA based
assays. We have reported the prognostic value of a ‘‘one off’’
RNA based test for E6 and E7 mRNA transcripts.17 HPV viral
load measurement may also be predictive of future cervical
neoplasia and a linear association between increasing grade
of cervical intraepithelial neoplasia lesions and HPV-16 viral
load has been noted.4 18 19 However, systems for measuring
cumulative viral load may overestimate type specific loads
within multiple HPV infections.19 Moreover, it has been
suggested that there may be type specific differences in the
clinical usefulness of viral load.19 In addition, technical
limitations associated with multiplexing HPV type specific
quantitative assays on real time polymerase chain reaction
platforms make this approach, at least at present, unsuitable
for detecting the diverse range of HR-HPV types within
screening populations.
This prospective population based study in Scotland has
shown that women infected with multiple HPV types at
baseline were no more likely to develop cervical dyskaryosis
after two to three years than those with a single HR-HPV
infection. Women who had persistent HR-HPV infections
were at greater risk of developing cervical neoplasia
compared with those who cleared HPV (p = 0.0001) or
those who were sequentially infected with different HPV
types (p = 0.001). All high grade cervical neoplasms were
Table 4 Persistent and sequential human papillomavirus (HPV) infections and clearance of HPV infection related to evidence of
cervical cytological dyskaryosis at follow up
Follow up cervical cytology result
(total no.)
HPV type specific
persistent infection Sequential HPV infection
Clearance of HPV
infection Untypeable* HPV infection
Negative (110) 17 35 55 3
Borderline (3) 1 2 0 0
Mild (9) 7 1 1 0
Moderate (2) 2 0 0 0
Severe (2) 2 0 0 0
All 29 38 56 3
*3 specimens were HPV positive at baseline and follow up but could not be assigned to either HPV persistent or sequential infections because the specific HPV type
could not be determined; therefore, they were excluded from subsequent analysis.
Table 5 Prevalence and persistence of HPV types
detected at baseline and follow up
HPV type Baseline Follow up % Persistence
HR-HPV type
16 33 16 48.5
18 10 2 20.0
31 10 1 10.0
33 5 3 60.0
35 1 0 0
39 1 0 0
45 7 1 14.3
51 12 0 0
52 6 1 16.7
53 9 1 11.1
56 7 2 28.6
58 6 2 33.3
59 7 4 57.1
66 9 1 11.1
68 2 0 0
73 7 0 0
82 1 0 0
Total HR-HPV 133 34 25.6%
LR-HPV type
6 5 0 0
11 2 0 0
40 2 0 0
42 9 2 22.2
54 2 0 0
55 2 1 50.0
57 1 0 0
83 1 0 0
84 3 0 0
Total LR-HPV 27 3 11.1%
Human papillomavirus (HPV) types within mixed infections are described
separately. The table is subdivided into high risk (HR) and low risk (LR)
HPV types and their totals are calculated.
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detected in women over 30 years and all were associated with
persistent HR-HPV infection. Thus, we conclude that
repeated HPV genotyping could be used to monitor type
specific persistent HR-HPV infection as a means of identify-
ing women at increased risk of cervical neoplasia. This
approach could prove more accurate than either a one off
HPV test or a repeated presence–absence HPV test. The cost
effectiveness of such an approach should be investigated by
an appropriate, large scale cost–benefit analysis.
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Take home messages
N Women infected with multiple human papillomavirus
(HPV) types were no more likely to develop cervical
dyskaryosis after two to three years than those with a
single high risk (HR) HPV infection
N Women with persistent HR-HPV infections were at
greater risk of developing cervical neoplasia than those
who cleared HPV or were sequentially infected with
different HPV types
N All high grade cervical neoplasms were detected in
women over 30 years and all were associated with
persistent HR-HPV infection
N Thus, repeated HPV genotyping could be used to
monitor type specific persistent HR-HPV infection as a
means of identifying women at increased risk of
cervical neoplasia, and might be more accurate than
either a one off HPV test or a repeated presence/
absence HPV test
N The cost effectiveness of such an approach should be
investigated by an appropriate, large scale cost–
benefit analysis
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